Pfizer (PFE) has entered into three settlement agreements for VYNDAMAX. As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031.
Importance
Level 1
- Deals with: Dexcel Pharma, Hikma Pharmaceuticals (HIK LN) and Cipla (CIPLA)